BACKGROUND: The increasing global prevalence of pulmonary nontuberculous mycobacteria (NTM) disease has called attention to challenges in NTM diagnosis and management. This study was conducted to understand management and outcomes of patients with pulmonary NTM disease at diverse centers across the United States. METHODS: We conducted a 10-year (2005-2015) retrospective study at 7 Vaccine and Treatment Evaluation Units to evaluate pulmonary NTM treatment outcomes in human immunodeficiency virus-negative adults. Demographic and clinical information was abstracted through medical record review. Microbiologic and clinical cure were evaluated using previously defined criteria. RESULTS: Of 297 patients diagnosed with pulmonary NTM, the most frequent NTM species were Mycobacterium avium-intracellulare complex (83.2%), M. kansasii (7.7%), and M. abscessus (3.4%). Two hundred forty-five (82.5%) patients received treatment, while 45 (15.2%) were followed without treatment. Eighty-six patients had available drug susceptibility results; of these, >40% exhibited resistance to rifampin, ethambutol, or amikacin. Of the 138 patients with adequate outcome data, 78 (56.5%) experienced clinical and/or microbiologic cure. Adherence to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) treatment guidelines was significantly more common in patients who were cured (odds ratio, 4.5, 95% confidence interval, 2.0-10.4; P < .001). Overall mortality was 15.7%. CONCLUSIONS: Despite ATS/IDSA Guidelines, management of pulmonary NTM disease was heterogeneous and cure rates were relatively low. Further work is required to understand which patients are suitable for monitoring without treatment and the impact of antimicrobial therapy on pulmonary NTM morbidity and mortality.
BACKGROUND: The increasing global prevalence of pulmonary nontuberculous mycobacteria (NTM) disease has called attention to challenges in NTM diagnosis and management. This study was conducted to understand management and outcomes of patients with pulmonary NTM disease at diverse centers across the United States. METHODS: We conducted a 10-year (2005-2015) retrospective study at 7 Vaccine and Treatment Evaluation Units to evaluate pulmonary NTM treatment outcomes in human immunodeficiency virus-negative adults. Demographic and clinical information was abstracted through medical record review. Microbiologic and clinical cure were evaluated using previously defined criteria. RESULTS: Of 297 patients diagnosed with pulmonary NTM, the most frequent NTM species were Mycobacterium avium-intracellulare complex (83.2%), M. kansasii (7.7%), and M. abscessus (3.4%). Two hundred forty-five (82.5%) patients received treatment, while 45 (15.2%) were followed without treatment. Eighty-six patients had available drug susceptibility results; of these, >40% exhibited resistance to rifampin, ethambutol, or amikacin. Of the 138 patients with adequate outcome data, 78 (56.5%) experienced clinical and/or microbiologic cure. Adherence to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) treatment guidelines was significantly more common in patients who were cured (odds ratio, 4.5, 95% confidence interval, 2.0-10.4; P < .001). Overall mortality was 15.7%. CONCLUSIONS: Despite ATS/IDSA Guidelines, management of pulmonary NTM disease was heterogeneous and cure rates were relatively low. Further work is required to understand which patients are suitable for monitoring without treatment and the impact of antimicrobial therapy on pulmonary NTM morbidity and mortality.
Authors: Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots Journal: Am J Respir Crit Care Med Date: 2012-02-03 Impact factor: 21.405
Authors: Jakko van Ingen; Dirk Wagner; Jack Gallagher; Kozo Morimoto; Christoph Lange; Charles S Haworth; R Andres Floto; Jennifer Adjemian; D Rebecca Prevots; David E Griffith Journal: Eur Respir J Date: 2017-02-15 Impact factor: 16.671
Authors: Kenneth N Olivier; David E Griffith; Gina Eagle; John P McGinnis; Liza Micioni; Keith Liu; Charles L Daley; Kevin L Winthrop; Stephen Ruoss; Doreen J Addrizzo-Harris; Patrick A Flume; Daniel Dorgan; Matthias Salathe; Barbara A Brown-Elliott; Renu Gupta; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2017-03-15 Impact factor: 21.405
Authors: E Tanaka; T Kimoto; K Tsuyuguchi; I Watanabe; H Matsumoto; A Niimi; K Suzuki; T Murayama; R Amitani; F Kuze Journal: Am J Respir Crit Care Med Date: 1999-09 Impact factor: 21.405
Authors: Roland Diel; Albert Nienhaus; Felix C Ringshausen; Elvira Richter; Tobias Welte; Klaus F Rabe; Robert Loddenkemper Journal: Chest Date: 2018-02-02 Impact factor: 9.410
Authors: Megan E Billinger; Kenneth N Olivier; Cecile Viboud; Ruben Montes de Oca; Claudia Steiner; Steven M Holland; D Rebecca Prevots Journal: Emerg Infect Dis Date: 2009-10 Impact factor: 6.883
Authors: Grace Wang; Jack T Stapleton; Arthur W Baker; Nadine Rouphael; C Buddy Creech; Hana M El Sahly; Jason E Stout; Lisa Jackson; Edward Charbek; Francisco J Leyva; Kay M Tomashek; Melinda Tibbals; Aaron Miller; Sharon Frey; Samson Niemotka; Timothy L Wiemken; Nour Beydoun; Ghina Alaaeddine; Nicholas Turner; Emmanuel B Walter; Robin Chamberland; Getahun Abate Journal: Open Forum Infect Dis Date: 2022-07-26 Impact factor: 4.423